A phase i study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 3, 2010, Pages 242-245

  Malik, Imtiaz ^a   Hussein, Farabi ^b   Bush, David ^c   Alqaisi, Munther ^f   Bernal, Pedro ^a   Byrd, Janet ^d   Garberoglio, Carlos ^e  

^a Loma Linda Oncology Medical Group Inc   (United States)

^b ARROWHEAD REGIONAL MEDICAL CENTER   (United States)

^c LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^d LOMA LINDA UNIVERSITY HEALTH   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f Mojave Radiation Oncology Center   (United States)

Author keywords

Capecitabine; Celecoxib; Chemoradiation; Irinotecan; Rectal cancer

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; CAPECITABINE; CELECOXIB; IRINOTECAN;

ADULT; ADVANCED CANCER; ANEMIA; ANUS SPHINCTER; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; ECHOGRAPHY; FATIGUE; FEMALE; GANGRENE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL VASCULAR DISEASE; PHASE 1 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PROSPECTIVE STUDY; RADIATION DOSE; RECOMMENDED DRUG DOSE; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CARCINOMA; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; DIARRHEA; FECAL INCONTINENCE; FEMALE; FLUOROURACIL; GANGRENE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOADJUVANT THERAPY; PROCTITIS; PYRAZOLES; RADIATION INJURIES; RADIATION-SENSITIZING AGENTS; RECTAL NEOPLASMS; SULFONAMIDES;

EID: 77953349643     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181a650fb     Document Type: Article

References (35)

1. Sauer R, Becker Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-1734.
2. Mohiuddin M, Hayne M, Regine WF, et al. Prognostic significance of post-chemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys. 2000;48:1075-1080.
3. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688-8696.
4. Stipa F, Chessin DB, Shia J, et al. A pathologic complete response of rectal cancer to preoperative combined- modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. Ann Surg Oncol. 2006; 13:1047-1053.
5. Das P, Skibber JM, Rodriguez-Bigas MA, et al. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol. 2006;29:219-224.
6. Bujko K, Michalski W, Kepka L, et al. Association between pathologic response in metastatic lymphnodes after preoperative chemoradiation and risk of distant metastases in rectal cancer: an analysis of outcomes in a randomized trial. Int J Radiat Oncol Biol Phys. 2007;67:369-377.
7. Capirci C, Valentini V, Cionini L, et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 pCR patients. Int J Radiat Oncol Biol Phys. In press.
8. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissues. Eur J Cancer. 1998;34:1274-1281.
9. Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-FU by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol. 1998;55:1091-1097.
10. Schüller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291-297.
11. Takebayashi Y, Akiyama S, Akiba S, et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst. 1996;88:1110-1117.
12. Ishikawa T, Sekiguchi F, Fukase Y, et al. Positive correlation between efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. 1998;58:685-690.
13. Sawada N, Ishikawa T, Sekiguchi F, et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999;10:2948-2953.
14. Van Custem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097-4106.
15. Hoff P, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282-2292.
16. Vanhoefer U, Harstrick A, Achterrath W, et al. Irinotecan in the treatment of coloractal cancer: clinical overview. J Clin Oncol. 2001;19:1501-1518.
17. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995;55:3785-3789.
18. Dimberg J, Samuelsson A, Hugander A, et al. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut. 1999;45:730-732.
19. Davis TW, Hunter N, Trifan OC, et al. COX-2 inhibitors as radiosensitizing agents for cancer therapy. Am J Clin Oncol. 2003;26:S58-S61.
20. Liu G, Franssen E, Fitch MI, et al. Patients preference for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110-115.
21. Kim JC, Kim TW, Kim JH, et al. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2005;63:346-353.
22. Krishnan S, Janjan NA, Skibber MA, et al. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006;66:762-771.
23. Das P, Lin EH, Bhatia S, et al. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-Fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 2006;66:1378-1383.
24. Kim DY, Jung KH, Kim TH, et al. Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2007;67:378-384.
25. Klautke G, Kuchenmeister U, Foitzik T, et al. Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer. 2006;94:976-981.
26. Willeke F, Horisberger K, Kraus-Tiefenbacher U, et al. Phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (Capiri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer. 2007;96:912-917.
27. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclooxygenase- 2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage nonsmall cell-lung cancer. J Clin Oncol. 2003;21: 2645-2650.
28. Edleman MJ, Watson DM, Wang X, et al. Eicosanoid modulation in advanced nonsmall cell lung cancer (NSCLC); CALGB 30203[Abstract 7025]. J Clin Oncol. 2006;24:370s.
29. Javle MM, Cao S, Durani FA, et al. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. Clin Cancer Res. 2007;13:965-971.
30. Lin EH, Curley SA, Crane CC, et al. Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? Am J Clin Oncol. 2006; 29:232-239.
31. Lilenbaum R, Socinski MA, Altorki Nk, et al. A randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of nonsmall cell lung cancer. J Clin Oncol. 2006; 24:4825-4832.
32. Fuchs C, Marshall J, Mitchell E, et al. A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C) [Abstract 3506]. J Clin Oncol. 2006;24: 146s.
33. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959. (Pubitemid 33010342)
34. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080.
35. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102.